ASH’s multidisciplinary panel provides a standardized diagnostic pathway emphasizing early laboratory testing and surrogate biopsies.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 has published new clinical practice guidelines aimed at improving the early, timely, and accurate diagnosis of light chain (AL) amyloidosis.

The guidelines were published January 28, 2026, in 

 and outline best practices to support clinicians in recognizing and diagnosing AL amyloidosis, a disease frequently missed or diagnosed late due to its heterogeneous presentation.

“These guidelines will be a valuable resource not only for hematologists, but for clinicians across other specialties who care for patients with AL amyloidosis,” said Robert Negrin, MD, ASH President, in a statement. “Because this is a rare and often underrecognized disorder, these recommendations are particularly important for coordinating care and increasing awareness.”

AL amyloidosis is typically a multisystem disease, with amyloid deposits affecting multiple organs. The heart and kidneys are most commonly involved, potentially resulting in cardiomyopathy, renal failure, and pleural or pericardial effusions. Multiorgan dysfunction is strongly associated with poorer outcomes and reduced survival, while 51% to 80% of patients present with cardiac involvement, a major cause of morbidity and mortality in these patients.

The pathogenesis of AL amyloidosis is caused by the misfolding and tissue deposition of monoclonal immunoglobulin light chains produced by abnormal plasma cells. These amyloid deposits, along with circulating free light chains, disrupt normal tissue structure and function, leading to progressive organ damage and increased risk of death, particularly when diagnosis is delayed.

In the past, patients have reported diagnostic delays of >1 year from symptom onset, especially since the presenting symptoms are non-specific, and first-line clinicians may not have disease awareness.

For example, one primary risk factor for AL amyloidosis is increased age, with a median age at diagnosis of approximately 64 years. Since the disease often presents later in life, nonspecific symptoms such as fatigue, weight loss, or reduced appetite are frequently misattributed to aging or more common chronic conditions, contributing to prolonged diagnostic delays.

Despite existing diagnostic tools, the absence of a standardized, evidence-based diagnostic pathway has contributed to prolonged delays and missed diagnoses in AL amyloidosis.

To address this diagnostic gap, the multidisciplinary guideline panel included hematologists, cardiologists, a neurologist, a nephrologist, an internist, a pathologist, and one patient representative. For each recommendation, the Evidence-Based Practice and Impact Center at the University of Kansas Health System conducted systematic evidence reviews and developed GRADE Evidence-to-Decision frameworks to guide recommendations.

The guidelines recommend the use of blood and urine testing, including serum immunofixation, urine immunofixation, and serum free light chain assays, when clinical suspicion for AL amyloidosis exists. To confirm diagnosis, the panel supports the use of surrogate biopsies through combined bone marrow biopsy and fat pad sampling in most cases, while recognizing that target organ biopsies may be appropriate in select clinical scenarios.

“For these patients, time is of the essence,” said Vishal Kukreti, MD, chair of the ASH Guidelines on Diagnosis of Light Chain Amyloidosis and a malignant hematologist at Princess Margaret Cancer Centre, in a statement. “These guidelines will help clinicians across disciplines think of this disease in the right scenarios and provide them with the necessary tools to obtain a clear, accurate diagnosis as quickly as possible.”

Currently, the panel is developing follow-up guidelines focused on the treatment of AL amyloidosis.

ASH publishes clinical practice guidelines on diagnosis of light chain amyloidosis. EurekAlert! Published January 28, 2026. Accessed January 28, 2026. https://www.eurekalert.org/news-releases/1114078

‌McCausland KL, White MK, Guthrie SD, et al. Light Chain (AL) Amyloidosis: The Journey to Diagnosis. 

The Patient - Patient-Centered Outcomes Research

. 2017;11(2):207-216. doi:https://doi.org/10.1007/s40271-017-0273-5

Chatzileontiadou S, Zegkos T, Frouzaki C, et al. Real world data on light chain cardiac amyloidosis: Still a delayed diagnosis. 

. 2022;12. doi:https://doi.org/10.3389/fonc.2022.944503

‌Hester LL, Gifkins DM, Bellew KM, et al. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. 

. 2021;107(4):428-435. doi:https://doi.org/10.1111/ejh.13679

Articles

New clinical practice guidelines have been released to enhance the diagnosis of light chain (AL) amyloidosis, a condition often diagnosed late due to its varied presentation. These guidelines aim to assist clinicians across specialties in recognizing and diagnosing this rare disorder, which frequently involves multiple organs, particularly the heart and kidneys. The guidelines recommend specific blood and urine tests and biopsy methods to confirm diagnosis. A multidisciplinary panel developed these recommendations, and follow-up guidelines on treatment are currently in progress.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hematology

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

HCPLive_Horizontal_VideoThumbnails Logan Briggs (2).png

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

After years of setbacks and uncertainty, the therapeutic landscape for 

metabolic dysfunction–associated steatohepatitis (MASH) and metabolic dysfunction–associated steatotic liver disease (MASLD)

 has entered a decisive new phase. Once characterized by failed trials and a lack of approved therapies, the field has rapidly shifted toward cautious optimism, driven by regulatory clarity, advancing endpoints, and a deepening late-stage pipeline.

“It’s an exciting landscape,” Mazen Noureddin, MD, MHSc, professor of medicine at Houston Methodist Hospital and co-chairman of the Board for Summit and Pinnacle Clinical Research, told 

. “There used to be a pessimistic look on the field from patients and investors. Not so much from researchers, because we started seeing the light at the end of the tunnel and the difficult end points started being formalized back then, and now, in 2026 we're starting with 2 drugs approved, resmetirom and semaglutide.”

He describes 2026 as a pivotal “year of action” for MASH drug development, with 2027 poised to deliver critical outcomes. He notes that the field has already crossed an important threshold, with resmetirom and semaglutide receiving accelerated approvals, while confirmatory outcomes trials continue. Now, the focus is now on demonstrating long-term benefit, particularly the prevention of cirrhosis and hepatic decompensation.

Noureddin additionally highlights several late-stage programs that he believes will shape the next era of care, including the ongoing MAESTRO outcomes trial of resmetirom in patients with cirrhosis. He also points to the momentum around FGF21-based therapies, including efruxifermin, pegozafermin, and efimosfermin, noting multiple high-impact phase 2 publications and active phase 3 programs following major acquisitions by large pharmaceutical companies.

Beyond these programs, Noureddin underscores growing enthusiasm for dual- and triple-agonist approaches, including GLP-1/glucagon combinations now in phase 3 development. He also draws attention to emerging innovation earlier in the pipeline, such as gene therapy approaches targeting FGF21 and novel agents expected to deliver biopsy data in 2026.

Despite this progress, Noureddin also calls attention to persistent unmet needs, including effective therapies for patients with cirrhosis.

“That is doable, but we don't have it handy for the patients, and the clock is ticking in terms of [getting it to them] before they decompensate,” he said. “I would like to see a drug approved as soon as possible for this patient population in particular.”

He also references the development of combination treatment regimens and the urgent push to move away from liver biopsy as a trial requirement as unmet needs he wants to see addressed, but expresses optimism around recent progress in the development of treatments for metabolic dysfunction and alcohol-associated liver disease (MetALD).

Looking ahead, Noureddin says he believes the next 5 years will define the backbone of MASH treatment algorithms, even as progress in decompensated cirrhosis may take longer. Still, he characterizes the current moment as unprecedented and marked by momentum, collaboration, and hope for patients who have long lacked therapeutic options.

Editors’ note: Noureddin reports relevant disclosures with Gilead, GlaxoSmithKline, Madrigal, Novo Nordisk, Takeda, 89BIO, Altimmune, Boehringer Ingelheim, and others.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed January 28, 2026. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed January 28, 2026. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Brooks A. Efruxifermin Shows Potential for Fibrosis Reduction in Phase 2b MASH Cirrhosis Trial. HCPLive. May 9, 2025. Accessed January 28, 2026. 

https://www.hcplive.com/view/exfruxifermin-misses-primary-endpoint-phase-2b-compensated-mash-cirrhosis-trial

Brooks A. Pegozafermin Enters Phase 3 Clinical Trial Program for MASH, Fibrosis. HCPLive. March 12, 2024. Accessed January 28, 2026. 

https://www.hcplive.com/view/pegozafermin-enters-phase-3-clinical-trial-program-mash-fibrosis

Noureddin M. Once-Monthly Efimosfermin Alfa Shows Promise for MASH in Phase 2 Study. HCPLive. May 5, 2025. Accessed January 28, 2026. 

https://www.hcplive.com/view/once-monthly-efimosfermin-alfa-shows-promise-mash-in-phase-2-study

Videos

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Discussing Icotrokinra for Adolescents, Other Emerging Psoriasis Drugs, With Linda Stein Gold, MD

, held at the Grand Wailea hotel, featured a presentation titled ‘Best of the Best at Maui Derm’ highlighting some of the key recent data on emerging therapeutic agents.

This session was presented by Linda Stein Gold, MD, director of Dermatology Clinical Research for the Henry Ford Health System, and Jason Hawkes, MD, associate professor of dermatology at the University of California, Davis, in Sacramento. Stein Gold sat down with 

 to discuss some of the most notable information highlighted in this talk.

“I think that in 2026, we understand that we have options available for our psoriasis patients to get them under control better than we have in the past, and we have wonderful options in the topical arena. We have these new nonsteroidal options that actually allow us to get patients under control and keep them under control.”

Additionally, Stein Gold highlighted efficacy rates of some of the new nonsteroidals as higher than more traditional nonsteroidal options in the past. Such options may help to simplify the treatment regimens among patients with psoriasis. Stein Gold also highlighted biologic agents getting patients to clear or almost clear and working well for psoriatic arthritis (PsA). Stein Gold was later asked about any specific drugs on the horizon with a significant amount of data behind them.

“We have one oral agent, icotrakinra…and this is a drug that's actually an oral peptide,” Stein Gold said. “It's different from the small molecules in the biologic [realm], and it's been formulated to be better absorbed. This drug actually targets the IL-23 receptor.”

Stein Gold noted icotrokinra was developed to selectively bind the interleukin (IL)-23 receptor and inhibit IL-23–mediated signaling. The medication’s use in patients with moderate-to-severe plaque psoriasis was explored in a variety of phase 3 clinical trials, including LEAD, ADVANCE 1, and ADVANCE 2.2 Stein Gold’s talk at Maui Derm included a discussion of data in adolescent patients specifically.

“We had a recent readout there where the efficacy data is really quite good, long term data does not show any safety signals that we seem to be concerned about,” Stein Gold explained. “We know that when we stop treatment with this drug, we see that we have about 8 - 12 weeks before we lose a PASI 90 or a PASI 75 response.”

For any additional information on these topics, view Stein Gold’s full interview posted above. To find out more from Maui Derm, view the 

The quotes contained in this interview were edited for clarity.

Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. AWA has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Arcutis, BMS, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Leo Pharma, Novartis, Parexel, Pfizer, Regeneron, Sanofi, Takeda, and UCB. RB is an advisory board member, consultant, speaker, investigator for, or received honoraria or grants from AbbVie, Alumis, Amgen, AnaptysBio, Arcutis, BMS/Celgene, Eli Lilly, Johnson & Johnson, LEO Pharma, Organon, Nimbus, Takeda, UCB, VentyxBio, Vyne, Xencor, and Zurabio, and is also an employee and shareholder of Innovaderm Research.

Stein Gold L, Hawkes J. Best of the Best at Maui Derm. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Armstrong A, et al. Comparative analysis of icotrokinra and approved advanced treatments for achievement of completely clear skin in patients with moderate-to-severe psoriasis: A systematic literature review and network meta-analysis. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29. Accessed January 28, 2026.

This interview at the 2026 Maui Derm Hawaii meeting features a discussion of new and emerging therapies in psoriasis, including icotrokinra.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

Liver Lineup: Updates and Unfiltered Insights

, Nancy Reau, MD, and Kimberly Brown, MD, turn their attention to 

metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH)

, conditions that now dominate hepatology clinics but continue to pose major diagnostic and therapeutic challenges. As new drugs enter the clinic and others advance through the pipeline, the hosts explore what meaningful progress looks like in a disease space defined by heterogeneity, comorbidities, and ongoing uncertainty around long-term outcomes.

The conversation opens with reflections on the transition from NAFLD/NASH to MASLD/MASH. Reau and Brown discuss how the updated terminology better captures the metabolic underpinnings of the disease and may help reduce stigma, while acknowledging that changing nomenclature alone does not solve longstanding issues around diagnosis, risk stratification, or patient engagement. They emphasize that many patients with advanced disease are still being identified late in their clinical course.

A central theme of the episode is how clinicians should think about treatment in MASH today. The hosts discuss the significance of having a therapy available for this patient population and what that means for hepatology practice. They underscore the importance of appropriate patient selection, fibrosis assessment, and setting realistic expectations around treatment goals, particularly given the complexity and heterogeneity of the disease.

Reau and Brown also address the role of weight loss and metabolic management in MASLD and MASH. They discuss how improvements in metabolic parameters can translate into liver-related benefits, while noting that sustained lifestyle change remains difficult to achieve and maintain. Pharmacologic approaches that support weight loss are discussed in the context of their broader metabolic effects, rather than as liver-specific therapies.

The episode concludes with a discussion of system-level challenges, including underdiagnosis, inconsistent use of noninvasive testing, and limited awareness outside of hepatology. As MASLD becomes an increasingly common cause of advanced liver disease, the hosts stress the need for better collaboration across specialties and clearer pathways for identifying patients who would benefit from referral and treatment.

Editors’ note: Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Podcasts

Reau and Brown discuss new data on MASH/MASLD, including awareness, referral patterns, discussions around alcohol, and emerging pharmacotherapies.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

 has approved a labeling supplement permitting repeat administration of iDose TR (travoprost intracameral implant) for the reduction of intraocular pressure (IOP) in patients with 

Drug: iDose TR (travoprost intracameral implant)

Class: Prostaglandin analog, sustained-release intracameral therapy

Indication: Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension

Regulatory Action: FDA approval of labeling supplement allowing repeat administration

Key Evidence: Phase 3 and phase 2b trials showing favorable corneal endothelial safety through 3 years; 12-month safety data from an implant exchange study

Key Safety Signals: Iritis, ocular hyperemia, increased IOP, iris pigmentation; contraindicated in patients with corneal endothelial disease or prior corneal transplantation

Regulatory Status: FDA-approved in the United States

Announced on January 28, 2026, this update modifies prior labeling that limited use to a single administration and is based on accumulated clinical safety data, including corneal endothelial outcomes, submitted by the manufacturer.

Glaucoma remains a leading cause of irreversible blindness worldwide, with IOP reduction as the only proven modifiable risk factor.

 Prostaglandin analog eye drops are widely recommended as first-line therapy due to their efficacy and once-daily dosing.

 However, real-world adherence to topical therapy is suboptimal, with studies estimating that 30% to 50% of patients do not use drops as prescribed. Factors include ocular surface disease, difficulty with instillation, cost, and treatment fatigue.

Procedural drug delivery approaches, including intracameral implants, aim to bypass adherence barriers while providing sustained IOP control. Until recently, these strategies were constrained by questions surrounding repeatability, reversibility, and long-term corneal safety—particularly endothelial cell loss, a known risk with intraocular devices and procedures.

For clinicians managing chronic glaucoma, the labeling change addresses a practical limitation of long duration intracameral therapy: how to maintain sustained prostaglandin exposure beyond the life of an initial implant while preserving corneal safety. Repeat dosing may expand the role of procedural pharmacotherapy for patients who struggle with adherence or tolerability of topical medications, although long-term comparative effectiveness data remain limited.

iDose TR is a titanium-based intracameral implant that continuously elutes a proprietary, preservative-free formulation of travoprost into the anterior chamber via membrane-controlled diffusion. The device contains 75 µg of travoprost and is implanted through the trabecular meshwork into the scleral tissue. The FDA originally approved iDose TR in 2023 for a single administration to reduce IOP in adults with OAG or OHT.

Travoprost is a prostaglandin F2α analog that lowers IOP by increasing uveoscleral outflow. Its efficacy and safety as a topical agent are well established. iDose TR represents an extension of this mechanism via continuous intraocular delivery rather than episodic topical dosing.

The newly approved labeling supplement allows re-administration in patients who maintain a “healthy cornea,” defined by corneal endothelial cell density parameters outlined in the updated prescribing information. According to the new label, repeat administration requires removal of the original implant and intracameral placement of a new device under standard aseptic conditions.

The approval was supported by pooled corneal safety data from phase 3 pivotal trials and a phase 2b study, which followed patients for up to 3 years after implantation. In these studies, no clinically significant corneal endothelial cell loss was observed over time. The manufacturer also cited results from an “exchange” study evaluating removal of the original implant and placement of a second iDose TR, with 12 months of follow-up demonstrating acceptable safety and tolerability. As of this writing, peer-reviewed publication of the exchange trial data is limited, and detailed efficacy outcomes following re-administration have not been widely reported.

Across controlled studies of single administration, commonly reported ocular adverse reactions (2%–6%) included increased IOP, iritis, dry eye, ocular hyperemia, eye pain, visual field defects, and reduced visual acuity. Consistent with other prostaglandin analogs, increased iris pigmentation has been reported and may be permanent.

In the phase 3 GC-010 and GC-012 trials, iDose TR demonstrated sustained IOP reduction comparable to topical timolol through 12 months, with durability extending beyond 24 months in extension analyses. These trials primarily evaluated a single implant, and while efficacy waned over time in some patients, corneal safety outcomes were favorable, supporting further investigation of repeat use.

However, the labeling update does not establish superiority over topical therapy or other sustained-release options, nor does it define optimal timing for re-administration. Head-to-head comparisons with other long-acting approaches, such as bimatoprost intracameral implants, are lacking.

Evidence supporting repeat administration is primarily safety-focused, with limited published data on long-term efficacy after reimplantation. Real-world outcomes, cost-effectiveness, and patient-reported measures will be critical to defining the role of repeat intracameral therapy in routine practice. Ongoing postmarketing surveillance and future comparative studies will be needed to clarify these questions.

Glaukos Corporation. Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR. 

. January 28, 2026. Accessed January 28, 2026. 

https://www.businesswire.com/news/home/20260128062505/en/Glaukos-Announces-US-FDA-Approval-of-NDA-Supplement-Allowing-for-Re-Administration-of-iDose-TR

Glaukos Corporation. Glaukos Announces FDA Approval of iDose TR (travoprost intracameral implant). December 14, 2023. Accessed January 28, 2026. 

https://investors.glaukos.com/news/news-details/2023/Glaukos-Announces-FDA-Approval-of-iDoseTR-travoprost-intracameral-implant/default.aspx

Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. 

Singh IP, Berdahl JP, Sarkisian SR, et al. Long-term safety and efficacy evaluation of Travoprost intracameral implant based on pooled analyses from two phase III trials. Drugs. 2024;84(10):1299-1311. 

Prum BE Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern. 

https://www.aaojournal.org/article/S0161-6420(15)01276-2/pdf

Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence. Ophthalmology. 2015;122(7):1308-1316. 

Lass JH, Benetz BA, Gal RL, et al. Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Ophthalmology. 2013;120(10):1949-1956. 

Netland PA, Gross RL, Peace JH, et al. Long-term efficacy and safety of travoprost compared with timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-484. 

Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: 24-month results from a phase 1/2 clinical trial. Ophthalmology. 2017;124(12):1687-1694. 

The FDA has approved repeat administration of iDose TR, a travoprost intracameral implant, for patients with open-angle glaucoma or ocular hypertension. This update, based on clinical safety data, addresses adherence issues associated with topical therapies. iDose TR offers sustained intraocular pressure reduction through continuous drug delivery, bypassing barriers of topical administration. The approval is supported by safety data from clinical trials, although long-term efficacy and comparative effectiveness remain under investigation. Repeat administration requires removal and replacement of the implant, with ongoing studies needed to assess real-world outcomes.

The new approval allows for repeat administration of iDose TR, modifying the existing single-administration label.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

FDA News

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

In a 31-center phase 2 trial in 10 countries, apecotrep BI 764198 reduced proteinuria in patients with primary focal segmental glomerulosclerosis.  


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

Ruth Frikke-Schmidt, MD, PhD, is a professor and chief physician at Copenhagen University Hospital.

Frikke-Schmidt discusses the newfound genetic correlation between vascular-related dementia and an increased BMI, partially mediated by high blood pressure.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Connecting Vascular Dementia to Obesity and High Blood Pressure, With Ruth Frikke-Schmidt, MD, PhD

Alexander Mathioudakis, MD, PhD, from the biology department at The University of Manchester.

In this Q&A, Mathioudaki discusses the post-hoc FLAME trial, which links ICS and LAMA discontinuation to transient exacerbation risk in COPD.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.

Icotrokinra Data at Maui Derm 2026 Reaffirm Efficacy in Psoriasis

Neal Bhatia, MD, speaks in this interview regarding his discussion at Maui Derm Hawaii of new and emerging therapies in dermatology.

Discussing GLP-1s, New Dermatology Therapies in 2026, With Neal Bhatia, MD

Robert Negrin, MD, is president of the American Society of Hematology and a professor of medicine at Stanford University. 

ASH’s new president, Robert Negrin, explains key takeaways from the 67th meeting and sets the scene for ASH 2026. 


Looking Ahead to ASH’s 68th Meeting, With President Robert Negrin, MD

This interview from the Maui Derm 2026 conference features Lawrence Eichenfield, MD, discussing takeaways from his talk ‘Acne and Rosacea: Update 2026.’

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Rosacea

On the HCPLive rosacea page, resources on the topics of medical news and expert insight into acne rosacea can be found. Content includes articles, interviews, videos, podcasts, and breaking news on the skin condition, and more.

Acne and Rosacea Treatment Updates for 2026, With Lawrence Eichenfield, MD

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Anticipating The FDA Decision of Anaphylm for Anaphylaxis, With David Golden, MD

Andrew Kau, MD, PhD, is an associate professor in the John T. Milliken Department of Medicine at WashU Medicine.

Andrew Kau, MD, PhD, and Audrey John, MD, PhD, discuss their recent research exploring exhaled breath analysis as a noninvasive way to probe the gut microbiome.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exploring Exhaled Breath as a New Platform for Gut Microbiome-Based Diagnostics

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

Latest News

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

Discussing Icotrokinra for Adolescents, Other Emerging Psoriasis Drugs, With Linda Stein Gold, MD

Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension